当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2020-04-01 , DOI: 10.1021/acs.jmedchem.0c00045
Fumiyuki Shirai , Anna Mizutani 1 , Yoko Yashiroda , Takeshi Tsumura , Yuko Kano , Yukiko Muramatsu 1 , Tsubasa Chikada , Hitomi Yuki , Hideaki Niwa , Shin Sato , Kenichi Washizuka , Yasuko Koda , Yui Mazaki , Myung-Kyu Jang 1, 2 , Haruka Yoshida 1 , Akiko Nagamori 1 , Masayuki Okue , Takashi Watanabe , Kouichi Kitamura , Eiki Shitara , Teruki Honma , Takashi Umehara , Mikako Shirouzu , Takehiro Fukami , Hiroyuki Seimiya 1, 2 , Minoru Yoshida 3 , Hiroo Koyama
Affiliation  

Tankyrases (TNKS/TNKS2) belong to the poly(ADP-ribose) polymerase family. Inhibition of their enzymatic activities attenuates the Wnt/β-catenin signaling, which plays an important role in cancer pathogenesis. We previously reported the discovery of RK-287107, a spiroindoline-based, highly selective, potent tankyrase inhibitor. Herein we describe the optimization process of RK-287107 leading to RK-582, which exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered. In addition to the dose-dependent elevation and attenuation of the levels of biomarkers AXIN2 and β-catenin, respectively, results of the TCF reporter and cell proliferation studies on COLO-320DM are discussed.

中文翻译:

口服有效的基于螺吲哚啉酮的坦科聚合酶抑制剂的设计与发现。

坦科聚合酶(TNKS / TNKS2)属于聚(ADP-核糖)聚合酶家族。抑制其酶活性会减弱Wnt /β-catenin信号传导,这在癌症发病机理中起着重要作用。我们以前曾报道过发现基于螺二氢吲哚的,高度选择性的,有效的坦科聚合酶抑制剂RK-287107。在这里,我们描述了导致RK-582的RK-287107的优化过程,该过程在口服时在COLO-320DM小鼠异种移植模型中显示出明显改善的强大的肿瘤生长抑制作用。除了分别随剂量增加和减弱生物标志物AXIN2和β-catenin的水平外,还讨论了TCF报告基因和COLO-320DM细胞增殖研究的结果。
更新日期:2020-04-24
down
wechat
bug